Greg de Lissovoy

Summary

Affiliation: United BioSource Corporation
Country: USA

Publications

  1. doi request reprint Surgical site infection: incidence and impact on hospital utilization and treatment costs
    Gregory de Lissovoy
    United BioSource Corporation, 7101 Wisconsin Avenue, Bethesda, MD 20814, USA
    Am J Infect Control 37:387-97. 2009
  2. ncbi request reprint Measuring the burden of illness for end-stage renal disease: some heavy lifting required
    G de Lissovoy
    United BioSource Corp, Bethesda, Maryland 20814, USA
    Kidney Int 72:1045-7. 2007
  3. doi request reprint The costs of treating acute heart failure: an economic analysis of the SURVIVE trial
    Gregory de Lissovoy
    United BioSource Corporation, Center for Health Economics, Epidemiology and Science Policy, Bethesda, MD 20814, USA
    J Med Econ 11:415-29. 2008
  4. doi request reprint Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study
    Greg de Lissovoy
    United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Eur J Health Econ 11:185-93. 2010
  5. ncbi request reprint A prospective study of the cost-utility of the multichannel cochlear implant
    C S Palmer
    MEDTAP International, Bethesda, MD 20814, USA
    Arch Otolaryngol Head Neck Surg 125:1221-8. 1999
  6. ncbi request reprint Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective
    G de Lissovoy
    MEDTAP International, Bethesda, Maryland, USA
    Am J Manag Care 7:S535-8; discussion S538-44. 2001
  7. ncbi request reprint Relationship of hemoglobin A1c, age of diabetes diagnosis, and ethnicity to clinical outcomes and medical costs in a computer-simulated cohort of persons with type 2 diabetes
    G de Lissovoy
    MEDTAP International, Inc, Bethesda, MD 20814, USA
    Am J Manag Care 6:573-84. 2000

Detail Information

Publications7

  1. doi request reprint Surgical site infection: incidence and impact on hospital utilization and treatment costs
    Gregory de Lissovoy
    United BioSource Corporation, 7101 Wisconsin Avenue, Bethesda, MD 20814, USA
    Am J Infect Control 37:387-97. 2009
    ..Surgical site infections (SSIs) are serious operative complications that occur in approximately 2% of surgical procedures and account for some 20% of health care-associated infections...
  2. ncbi request reprint Measuring the burden of illness for end-stage renal disease: some heavy lifting required
    G de Lissovoy
    United BioSource Corp, Bethesda, Maryland 20814, USA
    Kidney Int 72:1045-7. 2007
    ..This Commentary describes the methodology of BOI analysis, its role in formulating public policy, and the potential application to improving care for ESRD...
  3. doi request reprint The costs of treating acute heart failure: an economic analysis of the SURVIVE trial
    Gregory de Lissovoy
    United BioSource Corporation, Center for Health Economics, Epidemiology and Science Policy, Bethesda, MD 20814, USA
    J Med Econ 11:415-29. 2008
    ....
  4. doi request reprint Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study
    Greg de Lissovoy
    United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Eur J Health Econ 11:185-93. 2010
    ..We report an economic analysis of REVIVE II from the hospital perspective...
  5. ncbi request reprint A prospective study of the cost-utility of the multichannel cochlear implant
    C S Palmer
    MEDTAP International, Bethesda, MD 20814, USA
    Arch Otolaryngol Head Neck Surg 125:1221-8. 1999
    ..Prior clinical studies have indicated that cochlear implantation provides benefits to individuals with advanced sensorineural hearing loss who are unable to gain effective speech recognition with hearing aids...
  6. ncbi request reprint Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective
    G de Lissovoy
    MEDTAP International, Bethesda, Maryland, USA
    Am J Manag Care 7:S535-8; discussion S538-44. 2001
    ..What is needed now is better evidence as a basis for decisions regarding DVT prophylaxis and clinical studies that track the long-term clinical and economic impact of DVT...
  7. ncbi request reprint Relationship of hemoglobin A1c, age of diabetes diagnosis, and ethnicity to clinical outcomes and medical costs in a computer-simulated cohort of persons with type 2 diabetes
    G de Lissovoy
    MEDTAP International, Inc, Bethesda, MD 20814, USA
    Am J Manag Care 6:573-84. 2000
    ..e., a sustained reduction in glycosylated hemoglobin (hemoglobin A1c [HbA1c]) on the lifetime incidence and direct medical costs of complications in persons with type 2 diabetes...